Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn
June 28, 2013
- Reasons for Doctors’ Reluctance to Generic Name Prescribing is Time and Effort: CareNet Survey
June 28, 2013
- Tsumura Reports Record Profits through Intensified MR Activities to Educate Doctors about Kampo Medicine
June 28, 2013
- Astellas Begins Global PIII Study of Cytomegalovirus Vaccine
June 27, 2013
- Shionogi Establishes New Chinese Subsidiary
June 27, 2013
- Astellas, Cytokinetics Agree to Develop, Commercialize Skeletal Muscle Activators
June 27, 2013
- Takeda Files BLA for CD, UC Treatment in US
June 27, 2013
- Eisai Launches Aricept Dry Syrup
June 26, 2013
- Eisai to Suspend Sales of Future Mainstay Antiepileptic Drug in Germany
June 26, 2013
- Success in Emerging Markets Key for Drug Makers’ Growth: IMS Japan Senior Principal
June 26, 2013
- Myelofibrosis Treatment Jakavi Reduced Risk of Death by 52% in 3-Year Follow-up Study: Novartis AG
June 26, 2013
- Anticancer Agent Xtandi Receives Approval Also in Europe: Astellas
June 26, 2013
- Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label
June 25, 2013
- Novartis AG Probing 10-Plus Years of Documents, Emails over Diovan Papers
June 25, 2013
- Taiho to Launch New Formulation TS-1, World’s 1st Anticancer OD Tablets
June 25, 2013
- UMN, API, Yakult Officially Agree on Joint Biosimilar Business
June 24, 2013
- Toho Holdings Targets 26.1 Billion Yen Operating Profit in FY2015
June 24, 2013
- Volibris Receives Orphan Drug Designation for Indication of CTEPH in Japan: GSK
June 24, 2013
- Kowa, Sanofi File NDAs for SGLT-2 Inhibitor Tofogliflozin in Japan
June 24, 2013
- Kitasato Daiichi Sankyo Vaccine Submits NDA for Cell-Based Pandemic Flu Vaccine
June 24, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…